|  |
Recap Roundup: 1Q 2010
Editor’s note: With the following article we kick off a new series of quarterly reports on deal-making activity in the biotechnology industry. Compiled by Deloitte Recap’s analysts, these high-level analyses not only enumerate the total number and value of therapeutic out-licensing deals and mergers and acquisitions on a quarterly basis, but also highlight the most important transactions that occurred during that time period. Moreover, each quarterly report will present an in-depth analysis of one specific deal that demonstrates a winning strategy in the drug-development game.
originally published 06/23/2010 |